Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: A short term natural history study

Multiple Sclerosis

Volumn 6, Issue 1, 2000, Pages 43-49

  Bagnato, F ^b   Tancredi, A ^b   Richert, N ^a   Gasperini, C ^b   Bastianello, S ^b   Bash, C ^a   McFarland, H ^a   Pozzilli, C ^b   Frank, J A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Building 10 ^*

Author keywords

Gadolinium enhancing lesions; Natural history; Relapsing remitting multiple sclerosis; Treatment trials

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 0034118424     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800678827437     Document Type: Article

References (27)

1. Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6-16.
2. Barkoff F, Hommes OR, Scheltens P, Walk J. (1991) Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 41: 1219-1222.
3. Edan G et al. (1997) Therapeutical effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62: 112-118.
4. Paty DW, Li DK. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Group. Neurology 43: 662-667
5. Pozzilli C et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61: 251-258.
6. Simon JH et al. (1998) Magnetic resonance studies of intramuscolar Interferon β-1a for relapsing multiple sclerosis. Ann Neurol 43: 679-687.
7. Stone LA et al. (1995) The effect of Interferon-β on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611-617.
8. Miller DH, Barkhof F, Nauta JJP. (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple slcerosis. Brain 116: 1077-1084.
9. Bastianello S et al. (1990) Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 40: 591-595.
10. Kermode AG et al. (1990) Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 113: 1477-1489.
11. Stone LA et al. (1995) Blood brain barrier disruption as measured by contrast enhanced MRI in patients with mild relapsing remitting multiple sclerosis: relationship to course, gender and age. Neurology 45: 1122-1126.
12. Hawkins CP et al. (1990) Duration and selectivity of Blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 113: 365-378.
13. Barkhof F et al. (1992) Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR 159: 1041 -1047.
14. Harris JO et al. (1991) Serial gadolinium- enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implication for clinical trials and natural history. Ann Neurol 29: 548-555.
15. McFarland HF et al. (1992) Using Gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
16. Albert PS et al. (1994) Repeated measures time series for modeling counts from relapsing-remitting disease: application to modeling disease activity in multiple sclerosis. Stat Med 13: 453-466.
17. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
18. Kurtzke JF et al. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
19. Agresti A. (1996) An introduction to categorical data analysis. Wile-Interscience publication USA, University of Florida.
20. Sormani MP et al. (1999) Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. J Neurol Neurosurg Psychiatry 66: 465-469.
21. Koudriavtseva T et al. (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 62: 285-287.
22. Molyneux PD et al. (1998) Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neur 43: 332-339.
23. Tubridy N et al. (1998) Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. Brain 121: 225-231.
24. Kappos et al. (1999) Predictive value of gadolinium-enhanced resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a metaanalysis. The Lancet 353: 964-969.
25. Filippi M et al. (1998) A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 121: 2011-2020.
26. Silver NC et al. (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120: 149-161.
27. Lee MA et al. (1999) Spatial mapping of T32 and gadolinium-enhancing T1 lesions volumes in multiple sclerosis: evidence for distinct mechanisms of lesions genesis? Brain 122: 1211-1212.